Limicol combination and LDL cholesterol health claim
An authorised disease-risk-reduction claim whose use remains restricted to the named applicant during the protected-data period. Authorisation alone does not establish that another operator may use it.
REGISTER STATUSAuthorisedConditions still apply
AUTHORISED WORDING
“A combination of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, procyanidolic oligomers from French maritime pine bark, garlic dry extract standardised in allicin, d-α-tocopheryl hydrogen succinate, riboflavin and inositol hexanicotinate reduces blood LDL-cholesterol concentrations. High LDL-cholesterol is a risk factor in the development of coronary heart disease.”
Limicol® specified combinationReduction of blood LDL-cholesterol concentrations
HEALTH CLAIM ENTITLEMENTLICENCE REQUIRED
Authorised claim — restricted use: you have not established entitlement.
Beneficiary
Laboratoire Lescuyer
Protected until
2028-04-10
General use from
2028-04-11
Licence evidence
MISSING
STATUSAUTHORISED
SUBSTANCELimicol® specified combination
RULE VERSIONSV-HC-LIMICOL-2026.09
LAST CHECKED2026-09-19
USE RIGHTLICENCE REQUIRED
01
CONDITIONS OF USE
Authorised does not mean unconditional
01
Use is restricted to Laboratoire Lescuyer for five years from 10 April 2023, unless another applicant obtains an authorisation without relying on the protected data or has the beneficiary’s agreement.
02
The food supplement must provide 600 mg artichoke leaf dry extract containing 30–36 mg caffeoylquinic acids and 500 mg red yeast rice containing 2 mg monacolin K.
03
It must also provide 10 mg sugar-cane derived policosanols, 20 mg French maritime pine bark extract containing 18 mg procyanidolic oligomers and 30 mg garlic dry extract containing 0.25 mg allicin.
04
The daily amount must also provide 30 mg alpha-tocopherol equivalents, 5 mg riboflavin and 9 mg inositol hexanicotinate, divided into three daily doses consumed with the major meals.
05
The authorisation of the claim does not authorise the ingredients, finished product or market placement; restrictions applying to monacolins and the complete presentation require separate review.
02
COMMON MARKETING VARIANTS
Where wording begins to drift
These are Suppvera’s illustrative review examples, not entries copied from the EU Register. A variant is assessed in its full consumer-facing context.
AUTHORISED · RESTRICTED USE
“A combination of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, procyanidolic oligomers from French maritime pine bark, garlic dry extract standardised in allicin, d-α-tocopheryl hydrogen succinate, riboflavin and inositol hexanicotinate reduces blood LDL-cholesterol concentrations. High LDL-cholesterol is a risk factor in the development of coronary heart disease.”
Official wording. Composition, dose, presentation and operator entitlement remain separate gates.
WORDING + ENTITLEMENT REVIEW
“The authorised Limicol combination helps reduce LDL cholesterol.”
A shortened disease-risk claim needs meaning, mandatory context, exact composition and entitlement review.
EVIDENCE CONTEXT NEEDED
“Clinically studied cholesterol support.”
The wording no longer states the authorised relationship and may imply a broader evidence package than the protected authorisation supports.
03
RISK EXAMPLES
Language that changes the promise
ENTITLEMENT NOT ESTABLISHED
“Our botanical blend uses the authorised Limicol claim.”
A third party cannot infer a right of use merely because the claim appears as authorised in the Register.
TREATMENT CLAIM
“Treats high cholesterol naturally.”
This changes a risk-factor relationship into treatment wording.
DIFFERENT PRODUCT + EFFECT
“Any red yeast rice supplement lowers LDL cholesterol.”
The authorisation concerns a precisely specified multi-component combination and does not extend to every red yeast rice product.
04
POLISH MARKET LAYER
Meaning must survive localisation
Verify the current Polish wording and every disease-risk statement required around the claim; a translation does not remove the applicant restriction.
Do not convert the protected claim into a general claim for red yeast rice or a single botanical ingredient.
05
EVIDENCE
Rule and source ledger
EU REGISTER CLAIM ID(S)Q-2012-00968
SCIENTIFIC REFERENCES IN LEGAL LISTEFSA Journal 2013;11(7):3327
SRC-01
European Commission
EU Register of nutrition and health claims
Claim status, conditions, restrictions and linked legal acts
